ICICI Direct recommended hold rating on Natco Pharma with a target price of Rs 595 in its research report dated May 28, 2019.
ICICI Direct's research report on Natco Pharma
Revenues de-grew 40.6% YoY to Rs 455.7 crore (I-direct estimate: Rs 541.5 crore) on the back of high base of gOseltamivir (flu) in the US. EBITDA margins were at 32.5% against 49.9% in Q4FY18 (I-direct estimate: 33.4%) mainly due to high base of gOseltamivir (flu) in the US. EBITDA de-grew 61.3% YoY to Rs 148.3 crore against I-direct estimates of Rs180.9 crore. Net profit de-grew 59.7% YoY to Rs120.8 crore (I-direct estimates: Rs134.4 crore).
he growth trajectory is likely to improve from FY22 onwards as the new strategy settles down. We value the stock on an SOTP basis. Accordingly, we arrive at our new target price of Rs 595, which includes base business value of ~Rs 400 (15x FY21E EPS of Rs 26.7) + Rs 195 for NPV of FTF/Para IVs in the US.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
The Great Diwali Discount!
Unlock 75% more savings this festive season. Get Moneycontrol Pro for a year for Rs 289 only.
Coupon code: DIWALI. Offer valid till 10th November, 2019 .